{"groups":[{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"FG000","title":"Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"FG001","title":"Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"FG002","title":"Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"FG003","title":"Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"FG004","title":"Cohort 5: Primary Central Nervous System Lymphoma"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"FG005","title":"Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"45"},{"groupId":"FG001","numSubjects":"32"},{"groupId":"FG002","numSubjects":"14"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"7"},{"groupId":"FG005","numSubjects":"11"}],"comment":"Underwent Leukapheresis","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"43"},{"groupId":"FG001","numSubjects":"27"},{"groupId":"FG002","numSubjects":"12"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"5"},{"groupId":"FG005","numSubjects":"10"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Pre-Treatment Period - Leukapheresis"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}],"type":"Participant Withdrew from Study"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"}],"type":"Physician Decision"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"43"},{"groupId":"FG001","numSubjects":"27"},{"groupId":"FG002","numSubjects":"12"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"5"},{"groupId":"FG005","numSubjects":"10"}],"comment":"Started lymphodepleting chemotherapy.","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"36"},{"groupId":"FG001","numSubjects":"27"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"5"},{"groupId":"FG005","numSubjects":"9"}],"comment":"Received conforming JCAR017 cell product.","type":"JCAR017 Treated Set"},{"achievements":[{"groupId":"FG000","numSubjects":"39"},{"groupId":"FG001","numSubjects":"24"},{"groupId":"FG002","numSubjects":"12"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"5"},{"groupId":"FG005","numSubjects":"9"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Treatment Period"}],"preAssignmentDetails":"During the pretreatment period participants underwent leukapheresis to enable JCAR017 cell product generation. Upon successful JCAR017 cell product generation, participants entered the treatment period and received lymphodepleting chemotherapy followed by infusion of JCAR017.\n\nCohort 6 was planned but subsequently removed from the study. No participants were enrolled into Cohort 6."}